VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, reported its Q2 2025 financial results and provided a business update. The company recorded $0.4 million in revenue for Q2, achieving 15% growth in H1 2025 compared to the previous year. Net loss decreased by 11% for Q2 and 24% for H1 year-over-year.
The company is actively pursuing commercialization of its Nu.Q庐 platform in human diagnostics, engaging in discussions with over ten companies. VolitionRx expects to sign its first human diagnostics agreement this quarter. Cash position stood at $2.3 million as of June 30, 2025, with an additional $1.2 million raised post-quarter through a registered direct offering.
VolitionRx (NYSE AMERICAN: VNRX), societ脿 multinazionale nel campo dell'epigenetica, ha comunicato i risultati finanziari del secondo trimestre 2025 e fornito un aggiornamento sulle attivit脿. La societ脿 ha registrato $0,4 milioni di ricavi per il Q2, conseguendo una crescita del 15% nel primo semestre 2025 rispetto all'anno precedente. La perdita netta 猫 diminuita del 11% nel Q2 e del 24% nel primo semestre su base annua.
L'azienda sta attivamente lavorando alla commercializzazione della sua piattaforma Nu.Q庐 per la diagnostica umana, con trattative in corso con oltre dieci societ脿. VolitionRx prevede di firmare il suo primo accordo per la diagnostica umana entro questo trimestre. La posizione di cassa era di $2,3 milioni al 30 giugno 2025, con ulteriori $1,2 milioni raccolti dopo la chiusura del trimestre tramite un'offerta diretta registrata.
VolitionRx (NYSE AMERICAN: VNRX), una empresa multinacional de epigen茅tica, inform贸 sus resultados financieros del segundo trimestre de 2025 y ofreci贸 una actualizaci贸n comercial. La compa帽铆a registr贸 $0,4 millones en ingresos en el Q2, logrando un crecimiento del 15% en el primer semestre de 2025 respecto al a帽o anterior. La p茅rdida neta se redujo un 11% en el Q2 y un 24% en el primer semestre interanual.
La empresa est谩 promoviendo activamente la comercializaci贸n de su plataforma Nu.Q庐 en diagn贸stico humano, manteniendo conversaciones con m谩s de diez compa帽铆as. VolitionRx espera firmar su primer acuerdo de diagn贸stico humano este trimestre. La posici贸n de caja era de $2,3 millones al 30 de junio de 2025, con $1,2 millones adicionales recaudados tras el cierre del trimestre mediante una colocaci贸n directa registrada.
VolitionRx (NYSE AMERICAN: VNRX), 雼り淡鞝� 頉勳儩鞙犾爠頃� 旮办梾鞚� 2025雲� 2攵勱赴 鞁れ爜瓿� 靷梾 順勴櫓鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2攵勱赴鞐� $0.4氚彪 毵れ稖鞚� 旮半頄堨溂氅�, 2025雲� 靸侂皹旮� 毵れ稖鞚� 鞝勲厔 雽�牍� 15% 歃濌皜頄堨姷雼堧嫟. 靾滌啇鞁れ潃 攵勱赴 旮办 11% 臧愳唽, 靸侂皹旮� 旮办鞙茧電� 24% 臧愳唽頄堨姷雼堧嫟.
須岇偓電� 鞚戈皠 歆勲嫧鞖� Nu.Q庐 頂岆灚韽� 靸侅毄頇旊ゼ 鞝侁饭 於旍頃橁碃 鞛堨溂氅� 10瓿� 鞚挫儊鞚� 旮办梾瓿� 雲检潣 欷戩瀰雼堧嫟. VolitionRx電� 鞚措矆 攵勱赴 雮挫棎 觳� 氩堨Ц 鞚戈皠 歆勲嫧 瓿勳暯鞚� 觳搓舶頃� 瓴冹溂搿� 旮半寑頃橁碃 鞛堨姷雼堧嫟. 2025雲� 6鞗� 30鞚� 旮办 順勱笀靹� 鞛愳偘鞚� $2.3氚彪鞚挫棃瓿�, 攵勱赴 頉� 霌彪 歆侅爲 瓿惦毳� 韱淀暣 於旉皜搿� $1.2氚彪鞚� 臁半嫭頄堨姷雼堧嫟.
VolitionRx (NYSE AMERICAN: VNRX), une soci茅t茅 multinationale sp茅cialis茅e en 茅pig茅n茅tique, a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 et fait le point sur ses activit茅s. La soci茅t茅 a enregistr茅 0,4 M$ de revenus au T2, r茅alisant une croissance de 15% au premier semestre 2025 par rapport 脿 l'ann茅e pr茅c茅dente. La perte nette a diminu茅 de 11% au T2 et de 24% au premier semestre en glissement annuel.
L'entreprise poursuit activement la commercialisation de sa plateforme Nu.Q庐 en diagnostic humain et est en discussion avec plus de dix soci茅t茅s. VolitionRx s'attend 脿 signer son premier accord en diagnostic humain ce trimestre. La tr茅sorerie s鈥櫭﹍evait 脿 2,3 M$ au 30 juin 2025, et 1,2 M$ suppl茅mentaires ont 茅t茅 lev茅s apr猫s la cl么ture du trimestre via une offre directe enregistr茅e.
VolitionRx (NYSE AMERICAN: VNRX), ein multinationales Epigenetik-Unternehmen, ver枚ffentlichte seine Finanzergebnisse f眉r das 2. Quartal 2025 und gab ein Gesch盲ftsupdate. Das Unternehmen erzielte im Q2 $0,4 Mio. Umsatz und verzeichnete im ersten Halbjahr 2025 gegen眉ber dem Vorjahr ein Wachstum von 15%. Der Nettoverlust sank um 11% im Q2 und um 24% im ersten Halbjahr im Jahresvergleich.
Das Unternehmen treibt die Kommerzialisierung seiner 狈耻.蚕庐-笔濒补迟迟蹿辞谤尘 f眉r die Human-Diagnostik aktiv voran und f眉hrt Gespr盲che mit mehr als zehn Firmen. VolitionRx rechnet damit, in diesem Quartal den ersten Vertrag f眉r Human-Diagnostik zu unterzeichnen. Die Zahlungsmittel betrugen zum 30. Juni 2025 $2,3 Mio., zudem wurden nach Quartalsende $1,2 Mio. durch ein registriertes Direct Offering aufgenommen.
- Revenue growth of 15% in first half 2025 compared to prior year
- Net loss reduction of 24% in H1 2025 year-over-year
- 30% reduction in net cash used in operating activities for H1 2025
- Advanced discussions with 10+ companies for Nu.Q庐 platform commercialization
- First human diagnostics licensing agreement expected this quarter
- Limited cash position of $2.3M, down from $3.3M in December 2024
- Required additional funding through registered direct offering
- Modest quarterly revenue of just $0.4M despite growth
Insights
Volition's Q2 shows modest revenue growth but concerning cash position despite reduced losses, with critical upcoming licensing deals needed.
Volition's Q2 2025 results paint a mixed financial picture that demands investor attention. The company generated
The critical concern lies in Volition's cash position. With only
The imminent licensing deals in the human diagnostics space represent a potential inflection point. Management's confidence in securing the first agreement this quarter suggests advanced negotiations, with multiple additional partnerships targeted this year. The structure of these deals - potentially including upfront payments, milestones, and recurring revenue similar to their veterinary market approach - will be crucial for addressing the company's financial stability. The mention of discussions with over ten companies across various stages from due diligence to contract finalization indicates a robust pipeline, but execution remains the key variable that will determine Volition's trajectory through 2025 and beyond.
Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m.
Cameron Reynolds, President and Group Chief Executive Officer, said:
"2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q庐 platform in the human diagnostics market and as reported previously we are in confidential discussions with more than ten companies.
"We are at various stages of the process across our different pillars ranging from due diligence, to tech transfer, to evaluation of clinical samples, to term sheet negotiation, and contract finalization. I am delighted to see things moving through the funnel, albeit confidentially at this stage, and expect to be able to sign our first agreement in the human diagnostics space this quarter.听
"We believe that our strong clinical evidence supports the broad applicability of our Nu.Q庐 technology in critical areas such as cancer and sepsis, including as a biomarker of interest to epigenetic drug development, an ever expanding area of focus for big pharma. 听
"Our goal is to secure multiple licensing agreements in the human diagnostics space this year, mirroring our successful strategy in the veterinary market. Similar to the veterinary market, we anticipate diverse deal structures, with potential for up front and milestone payments, and future recurring听revenue.
"Overall, we are making strong progress and expect the first human out licensing deal this quarter."
Financial Highlights
- Recorded just over
$0.4 million 15% over the prior year. - Net loss was down
11% for the quarter and24% for the first half compared to the prior year comparatives. - Net cash used in operating activities for the first half of 2025 was
$10.6 million 30% over the same period prior year. - Cash and cash equivalents as of June 30, 2025 totaled approximately
$2.3 million $3.3 million - Subsequent to quarter end we received
$1.2 million
Event:听听 VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call
Date:听听听听 Friday, August 15, 2025
Time:听听听 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID:听13755349
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer and Dr. Andrew Retter, Chief Medical Officer. The call will provide an update on important events that have taken place in the second quarter of 2025 and upcoming milestones.
A live audio webcast of the conference call will also be available on this . In addition, a telephone replay of the call will be available until August 29, 2025. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, [email protected]听+44 (0)7557 774620
Investor Relations:
Jeremy Feffer, LifeSci Advisors, [email protected] +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics鈩�, Capture-PCR鈩�, Capture-Seq鈩� and Nu.Q庐 and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
Video -
听
View original content to download multimedia:
SOURCE VolitionRx Limited
FAQ
What were VolitionRx (VNRX) Q2 2025 financial results?
How much cash does VolitionRx (VNRX) have as of Q2 2025?
What is the status of VolitionRx's Nu.Q庐 platform commercialization?
How has VolitionRx reduced its cash burn in 2025?
What are VolitionRx's business expectations for 2025?
